We provided statistical recommendations on reporting treatment effects and assessing the relationship between biomarkers and clinical endpoints for each class of biomarkers by using amyloid PET, plasma p-tau, and tau PET data from recent early symptomatic AD clinical trials as exemplars. Here, MAPT is linked to Alzheimer disease.